The Claim
Vitamin MK-7 supplementation for one year in postmenopausal women with osteopenia leads to a transient improvement in bone microarchitecture that is not sustained at three years, indicating that any early structural benefit is not clinically meaningful.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In postmenopausal women with low bone density, taking vitamin MK-7 for one year improves bone structure temporarily, but this improvement disappears by three years.
See the scientific wording
The transient improvement in bone microarchitecture observed after one year of vitamin MK-7 supplementation in postmenopausal women with osteopenia is not sustained at three years, suggesting any early structural benefit is not clinically meaningful.
Vitamin MK-7 activates a protein-modifying enzyme that attaches a chemical group to osteocalcin, allowing it to bind tightly to bone mineral. This temporarily strengthens bone structure, but the effect fades because bone cells stop responding to the increased mineralization signal over time, and no lasting structural change occurs.
What the research says
1 studyVitamin MK-7 seemed to help bone structure a little after one year, but after three years, it made no difference — bones got just as weak as in people who didn’t take it. So any early benefit didn’t last.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.